Evaluation of efalizumab using safe psoriasis control

BACKGROUND: Safe Psoriasis Control (SPC) is an important comprehensive measure that is validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab, a novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A, Henninger, Eric
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592297/
https://www.ncbi.nlm.nih.gov/pubmed/16984639
http://dx.doi.org/10.1186/1471-5945-6-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592297/
https://www.ncbi.nlm.nih.gov/pubmed/16984639
http://dx.doi.org/10.1186/1471-5945-6-8

Ejemplares similares